Breast Cancer Patients May Benefit From Extended Aromatase Inhibitor Treatment
Postmenopausal women lowered the risk of recurrent breast cancer -- or of new cancer arising in the other breast -- when they took a drug called an "aromatase inhibitor" for five years, according to research presented at the American Society of Clinical Oncology's annual meeting in Chicago.
An aromatase inhibitor blocks or suppresses estrogen, which some data suggest can keep cancer from returning. The study cited in Chicago involved almost 2,000 postmenopausal women who had already been treated, prior to the study, for at least five years with aromatase inhibitors.
"These data are important to millions of women around the world,” Dr. Harold J. Burstein, a spokesman for the American Society of Clinical Oncology said in a statement, adding that the study's data "suggest that longer durations of widely available therapy reduce the risk of cancer recurrence and prevent second cancers from arising."